Trials / Terminated
TerminatedNCT02465203
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
A Multi-centre 3-year Follow-up Study to Assess the Viral Activity in Patients Who Failed to Achieve Sustained Virologic Response in Novartis-sponsored Alisporivir-studies for Chronic Hepatitis C Patients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies
Detailed description
The purpose of this study was to follow patients from the feeder studies who have not achieved SVR24 to assess their viral activity, and to assess the changes in liver function and disease, and post-treatment safety over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Previous treatment in DEB025 study | Follow-up after DEB025 active study |
Timeline
- Start date
- 2012-09-06
- Primary completion
- 2014-01-23
- Completion
- 2014-01-23
- First posted
- 2015-06-08
- Last updated
- 2018-01-12
- Results posted
- 2018-01-12
Locations
40 sites across 16 countries: United States, Australia, Belgium, Canada, Germany, Hungary, India, Italy, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Thailand, Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02465203. Inclusion in this directory is not an endorsement.